• Explore /
  • Poster
  • / Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).

Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).

Abstract Poster

Authors

null

Hiroaki Akamatsu

Wakayama Medical University Hospital, Wakayama, Japan

Hiroaki Akamatsu , Hibiki Udagawa , Kentaro Tanaka , Masayuki Takeda , Shintaro Kanda , Keisuke Kirita , Shunsuke Teraoka , Kazuhiko Nakagawa , Yutaka Fujiwara , Ikuko Yasuda , Sumiko Okubo , Masayuki Shintani , Rachel S Leibman , Charity D. Scripture , Tomohide Tamura , Isamu Okamoto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03086239

Citation

J Clin Oncol 37, 2019 (suppl; abstr 8557)

DOI

10.1200/JCO.2019.37.15_suppl.8557

Abstract #

8557

Poster Bd #

313

Abstract Disclosures

Similar Posters

First Author: David F. McDermott

First Author: Hans Gelderblom

First Author: Gerald Steven Falchook

First Author: Himisha Beltran